{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:38:33Z","timestamp":1793162313931,"version":"4.5.0"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"S1","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7,1]]},"abstract":"<jats:p>Extrinsic and age-related intrinsic factors contribute to the development of facial lines, including lateral canthal lines (called crow\u2019s feet lines [CFL]) and horizontal forehead lines (FHL).<\/jats:p>\n          <jats:p>OnabotulinumtoxinA is a highly effective treatment for facial lines that inhibits acetylcholine release at the neuromuscular junction. This temporary chemical denervation leads to localized muscle relaxation and subsequent wrinkle reduction. Early studies of onabotulinumtoxinA treatment for facial neuronal disorders such as dystonia documented improvements in FHL and CFL. After the neurotoxin was approved for treating frown lines (glabellar lines [GL]), individuals requested treatment for other rhytids, and physicians continued assessing use in new areas. Once onabotulinumtoxinA was in clinical trial development, its efficacy and safety for CFL and FHL were successively evaluated as required by the US Food and Drug Administration and by key global health authorities, including those in the European Union, Japan, and China.<\/jats:p>\n          <jats:p>Allergan, collaborating with leading physicians, established clinical programs that included novel safety and efficacy measures to meet regulatory requirements. Global, phase 3, randomized, controlled studies of CFL and FHL met rigorous primary endpoints. Some countries mandated clinical trial data beyond US and European regulations, and Allergan conducted 11 studies in total, fulfilling diverse regulatory and study population data requirements.<\/jats:p>\n          <jats:p>Adverse events associated with local spread, including brow and eyelid ptosis, diplopia, headache, and eyelid sensory disorder, were infrequent and well tolerated. Consequently, onabotulinumtoxinA treatment of upper facial lines is now established globally as a highly effective, minimally invasive treatment for patients to achieve a natural appearance and look younger.<\/jats:p>","DOI":"10.1097\/md.0000000000032496","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T19:00:57Z","timestamp":1690484457000},"page":"e32496","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":25,"title":["Treatment of crow\u2019s feet lines and forehead lines with Botox (onabotulinumtoxinA): Development, insights, and impact"],"prefix":"10.1097","volume":"102","author":[{"given":"Alastair","family":"Carruthers","sequence":"first","affiliation":[{"name":"University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Carruthers","sequence":"additional","affiliation":[{"name":"University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koenraad","family":"De Boulle","sequence":"additional","affiliation":[{"name":"Aalst Dermatology Clinic, Aalst, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Lowe","sequence":"additional","affiliation":[{"name":"University of California, Los Angeles, CA, USA"},{"name":"Cranley Clinic, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Lee","sequence":"additional","affiliation":[{"name":"Allergan Aesthetics, an AbbVie Company, Irvine, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell F.","family":"Brin","sequence":"additional","affiliation":[{"name":"Allergan\/AbbVie, Irvine, CA, USA"},{"name":"University of California, Irvine, CA, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20240803","first-page":"168","article-title":"Botulinum toxin injection for facial wrinkles.","volume":"90","author":"Small","year":"2014","journal-title":"Am Fam Physician"},{"key":"R2-20240803","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1093\/asj\/sjw025","article-title":"OnabotulinumtoxinA for treatment of moderate to severe crow\u2019s feet lines: a review.","volume":"36","author":"Carruthers","year":"2016","journal-title":"Aesthet Surg J"},{"key":"R3-20240803","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/asj\/sjaa339","article-title":"The facial aging process from the \u201cinside out\u201d.","volume":"41","author":"Swift","year":"2021","journal-title":"Aesthet Surg J"},{"key":"R4-20240803","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1055\/s-0029-1243075","article-title":"Overview of facial aging.","volume":"25","author":"Beer","year":"2009","journal-title":"Facial Plast Surg"},{"key":"R5-20240803","doi-asserted-by":"crossref","first-page":"518e","DOI":"10.1097\/01.prs.0000475758.63709.23","article-title":"Global Aesthetics Consensus: botulinum toxin type 1\u2014evidence-based review, emerging concepts, and consensus recommendations for aesthetic use, including updates on complications.","volume":"137","author":"Sundaram","year":"2016","journal-title":"Plast Reconstr Surg"},{"key":"R6-20240803","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.jid.2017.04.002","article-title":"Lifestyle and physiological factors associated with facial wrinkling in men and women.","volume":"137","author":"Hamer","year":"2017","journal-title":"J Invest Dermatol"},{"key":"R8-20240803","doi-asserted-by":"crossref","first-page":"S274","DOI":"10.1097\/DSS.0000000000001414","article-title":"Forehead line treatment with onabotulinumtoxinA in subjects with forehead and glabellar facial rhytids: a phase 3 study.","volume":"43","author":"Fagien","year":"2017","journal-title":"Dermatol Surg"},{"issue":"suppl 1","key":"R9-20240803","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1097\/DSS.0000000000000146","article-title":"Effects of onabotulinumtoxinA treatment for crow\u2019s feet lines on patient-reported outcomes.","volume":"41","author":"Dayan","year":"2015","journal-title":"Dermatol Surg"},{"issue":"suppl 1","key":"R10-20240803","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/DSS.0000000000000275","article-title":"Patient satisfaction and safety with aesthetic onabotulinumtoxinA after at least 5 years: a retrospective cross-sectional analysis of 4,402 glabellar treatments.","volume":"41","author":"Trindade de","year":"2015","journal-title":"Dermatol Surg"},{"issue":"suppl 1","key":"R11-20240803","doi-asserted-by":"crossref","first-page":"S153","DOI":"10.1097\/DSS.0000000000000293","article-title":"Facial treatment preferences in aesthetically aware women.","volume":"41","author":"Narurkar","year":"2015","journal-title":"Dermatol Surg"},{"key":"R12-20240803","first-page":"1231","article-title":"Aesthetic procedures in office practice.","volume":"80","author":"Small","year":"2009","journal-title":"Am Fam Physician"},{"key":"R14-20240803","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1097\/DSS.0000000000001612","article-title":"Phase 3 study of onabotulinumtoxinA distributed between frontalis, glabellar complex, and lateral canthal areas for treatment of upper facial lines.","volume":"44","author":"De Boulle","year":"2018","journal-title":"Dermatol Surg"},{"key":"R15-20240803","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1097\/DSS.0000000000000704","article-title":"Repeated onabotulinumtoxinA treatment of glabellar lines at rest over three treatment cycles.","volume":"42","author":"Carruthers","year":"2016","journal-title":"Dermatol Surg"},{"key":"R16-20240803","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1097\/DSS.0000000000000128","article-title":"Efficacy and safety of onabotulinumtoxinA for the treatment of crow\u2019s feet lines: a multicenter, randomized, controlled trial.","volume":"40","author":"Carruthers","year":"2014","journal-title":"Dermatol Surg"},{"key":"R17-20240803","first-page":"924","article-title":"Pharmacologic weakening of extraocular muscles.","volume":"12","author":"Scott","year":"1973","journal-title":"Invest Ophthalmol"},{"key":"R18-20240803","first-page":"734","article-title":"Botulinum toxin injection of eye muscles to correct strabismus.","volume":"79","author":"Scott","year":"1981","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R19-20240803","first-page":"173","article-title":"Interventional neurology: treatment of neurological conditions with local injection of botulinum toxin.","volume":"54","author":"Brin","year":"1991","journal-title":"Arch Neurobiol (Madr)"},{"key":"R20-20240803","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1001\/archotol.1993.01880210108015","article-title":"Botulinum toxin for the treatment of hyperfunctional lines of the face.","volume":"119","author":"Blitzer","year":"1993","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"R21-20240803","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/00006534-199407000-00009","article-title":"Botulinum toxin A for hyperkinetic facial lines: results of a double-blind, placebo-controlled study.","volume":"94","author":"Keen","year":"1994","journal-title":"Plast Reconstr Surg"},{"key":"R22-20240803","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S0190-9622(96)90016-X","article-title":"Botulinum A exotoxin use in clinical dermatology.","volume":"34","author":"Carruthers","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"R23-20240803","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1524-4725.1992.tb03295.x","article-title":"Treatment of glabellar frown lines with C. botulinum-A exotoxin.","volume":"18","author":"Carruthers","year":"1992","journal-title":"J Dermatol Surg Oncol"},{"key":"R24-20240803","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00006534-198908000-00027","article-title":"Botulinum toxin: a treatment for facial asymmetry caused by facial nerve paralysis.","volume":"84","author":"Clark","year":"1989","journal-title":"Plast Reconstr Surg"},{"key":"R25-20240803","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1002\/mds.25582","article-title":"Diffusion, spread, and migration of botulinum toxin.","volume":"28","author":"Ramirez-Castaneda","year":"2013","journal-title":"Mov Disord"},{"key":"R26-20240803","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/DSS.0000000000001779","article-title":"OnabotulinumtoxinA for treatment of forehead and glabellar lines: subject-reported satisfaction and impact from a phase 3 double-blind study.","volume":"45","author":"Ogilvie","year":"2019","journal-title":"Dermatol Surg"},{"key":"R27-20240803","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/DSS.0000000000001883","article-title":"OnabotulinumtoxinA for simultaneous treatment of upper facial lines: subject-reported satisfaction and impact from a phase 3 study.","volume":"46","author":"Rivkin","year":"2020","journal-title":"Dermatol Surg"},{"key":"R28-20240803","doi-asserted-by":"crossref","first-page":"11861189","DOI":"10.1007\/s00266-017-0844-9","article-title":"OnabotulinumtoxinA (Botox) in the treatment of crow\u2019s feet lines in Japanese subjects.","volume":"41","author":"Harii","year":"2017","journal-title":"Aesthetic Plast Surg"},{"key":"R29-20240803","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1007\/s00266-008-9199-6","article-title":"A double-blind, randomized, placebo-controlled, two-dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects.","volume":"32","author":"Harii","year":"2008","journal-title":"Aesthetic Plast Surg"},{"key":"R30-20240803","doi-asserted-by":"crossref","first-page":"e2079","DOI":"10.1097\/GOX.0000000000002079","article-title":"Safety and efficacy of onabotulinumtoxinA for treatment of crow\u2019s feet lines in Chinese subjects.","volume":"7","author":"Wu","year":"2019","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"R32-20240803","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00042728-200503000-00001","article-title":"Double-blind, randomized, placebo-controlled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow\u2019s feet.","volume":"31","author":"Lowe","year":"2005","journal-title":"Dermatol Surg"},{"key":"R33-20240803","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/DSS.0000000000000626","article-title":"Efficacy and safety of onabotulinumtoxinA treatment of forehead lines: a multicenter, randomized, dose-ranging controlled trial.","volume":"42","author":"Solish","year":"2016","journal-title":"Dermatol Surg"},{"key":"R34-20240803","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/DSS.0000000000000220","article-title":"Efficacy and safety of onabotulinumtoxinA for treating crow\u2019s feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial.","volume":"41","author":"Moers-Carpi","year":"2015","journal-title":"Dermatol Surg"},{"key":"R35-20240803","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.jaad.2009.06.040","article-title":"Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: a meta-analysis of individual patient data from global clinical registration studies in 1678 participants.","volume":"61","author":"Brin","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"R36-20240803","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/DSS.0000000000000357","article-title":"A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of repeated onabotulinumtoxinA treatments in subjects with crow\u2019s feet lines and glabellar lines.","volume":"41","author":"Carruthers","year":"2015","journal-title":"Dermatol Surg"},{"key":"R37-20240803","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/DSS.0000000000002143","article-title":"Safety, efficacy, and patient satisfaction with onabotulinumtoxinA for the treatment of upper facial lines in Japanese subjects.","volume":"46","author":"Kawashima","year":"2020","journal-title":"Dermatol Surg"},{"key":"R38-20240803","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/ajd.13273","article-title":"Facial aesthetic injections in clinical practice: pretreatment and posttreatment consensus recommendations to minimise adverse outcomes.","volume":"61","author":"Goodman","year":"2020","journal-title":"Australas J Dermatol"},{"issue":"suppl 5","key":"R39-20240803","doi-asserted-by":"crossref","first-page":"33S","DOI":"10.1097\/01.PRS.0000082192.45787.B6","article-title":"Classification of crow\u2019s feet patterns among Caucasian women: the key to individualizing treatment.","volume":"112","author":"Kane","year":"2003","journal-title":"Plast Reconstr Surg"},{"key":"R41-20240803","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1111\/j.1524-4725.2006.32326.x","article-title":"Botulinum toxin type A treatment of multiple upper facial sites: patient-reported outcomes.","volume":"33","author":"Carruthers","year":"2007","journal-title":"Dermatol Surg"},{"key":"R42-20240803","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.jaad.2009.01.005","article-title":"A single-center, dose-comparison, pilot study of botulinum neurotoxin type A in female patients with upper facial rhytids: safety and efficacy.","volume":"60","author":"Carruthers","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"R43-20240803","doi-asserted-by":"crossref","first-page":"1S","DOI":"10.1097\/01.PRS.0000144795.76040.D3","article-title":"Consensus recommendations on the use of botulinum toxin type A in facial aesthetics.","volume":"114","author":"Carruthers","year":"2004","journal-title":"Plast Reconstr Surg"},{"issue":"suppl 1","key":"R44-20240803","first-page":"s7","article-title":"Expanding the use of neurotoxins in facial aesthetics: a consensus panel\u2019s assessment and recommendations.","volume":"9","author":"Kane","year":"2010","journal-title":"J Drugs Dermatol"},{"key":"R45-20240803","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/asj\/sjx179","article-title":"Impact of comprehensive, minimally invasive, multimodal aesthetic treatment on satisfaction with facial appearance: the HARMONY study.","volume":"38","author":"Weinkle","year":"2018","journal-title":"Aesthet Surg J"},{"key":"R47-20240803","doi-asserted-by":"crossref","first-page":"22049","DOI":"10.1038\/srep22049","article-title":"Hiding true emotions: micro-expressions in eyes retrospectively concealed by mouth movements.","volume":"6","author":"Iwasaki","year":"2016","journal-title":"Sci Rep"},{"key":"R48-20240803","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.cognition.2018.10.009","article-title":"Facial expressions of authenticity: emotion variability increases judgments of trustworthiness and leadership.","volume":"183","author":"Slepian","year":"2019","journal-title":"Cognition"},{"key":"R49-20240803","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1098\/rstb.2009.0189","article-title":"Darwin\u2019s contributions to our understanding of emotional expressions.","volume":"364","author":"Ekman","year":"2009","journal-title":"Philos Trans R Soc Lond B Biol Sci"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032496","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T01:55:59Z","timestamp":1722736559000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":44,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000032496","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,1]]}}}